Managing Menopausal Problems

  • Melody A. Cobleigh
Part of the Cancer Treatment and Research book series (CTAR, volume 103)


Breast cancer survivors often seek advice about menopausal problems from their oncologists. In addition, oncologists interact with colleagues about their patients’ menopausal issues. For these reasons, it is important that oncologists be knowledgeable about the effects of hormone replacement therapy (HRT) on overall health. And the need for up-to-the-minute information is intensified by the plethora of new drugs, the greater frequency with which pharmaceutical companies market directly to the public, and the increasing interest of patients in alternative therapies.


Breast Cancer Bone Mineral Density Postmenopausal Woman Hormone Replacement Therapy Breast Cancer Survivor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479.PubMedCrossRefGoogle Scholar
  2. 2.
    Poehlman ET, Toth MJ, Gardner AW. Changes in energy balance and body composition at menopause: A controlled longitudinal study. Ann Intern Med 1995; 123: 673.PubMedGoogle Scholar
  3. 3.
    The Writing Group for the PEPI Trial. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1997; 278: 1402.Google Scholar
  4. 4.
    Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight gain on breast cancer risk. JAMA 1997; 278: 1407PubMedCrossRefGoogle Scholar
  5. 5.
    Sporrong T, Hellgran M, Samsioe G, Mattson LA. Comparison of four continuously administered progestogen plus oestradiol combinations for climacteric complaints. Br J Obstet Gynecol 1998; 95: 1042Google Scholar
  6. 6.
    Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 1995; 13: 2737Google Scholar
  7. 7.
    Boulet MJ, Oddens BJ, Lehert P, Vemer HM, Viser A. Climacteric and menopause in seven south-east Asian countries. Maturitas 1994; 19: 157.PubMedCrossRefGoogle Scholar
  8. 8.
    Loprinzi CL, Pisansky TM, Fonseca R, et al. Pilot evaluation of venlaxafine hydrochloride’ for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998; 16: 2377.Google Scholar
  9. 9.
    Longacre TA, Bartow SA. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382.PubMedCrossRefGoogle Scholar
  10. 10.
    Potten CS, Watson RJ, Williams GT, Tickle S, Roberts SA, Harris M, Howell A. The effect of age and the menstrual cycle on the proliferative activity of the normal human breast. Br J Cancer 1988; 58: 163.PubMedCrossRefGoogle Scholar
  11. 11.
    Anderson TJ, Battersby S, King RJB, McPherson K, Going JJ. Oral contraceptive use influences resting breast proliferation. Hum Pathol 1989; 20: 1139PubMedCrossRefGoogle Scholar
  12. 12.
    Bergvist L, Adami Ho, Person I, et al. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1992; 130: 221Google Scholar
  13. 13.
    Huggins C, Yang NC. Induction and extinction of mammary cancer. Science 1962; 137: 257.PubMedCrossRefGoogle Scholar
  14. 14.
    Diamond JE, Hollander VP. Progesterone and breast cancer. Mt Sinai J Med 1979; 46: 225.PubMedGoogle Scholar
  15. 15.
    Jordan VC, MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long term tamoxifen therapy. J Natl Cancer Inst 1991; 83: 492.PubMedCrossRefGoogle Scholar
  16. 16.
    Kordon E, Lanari C, Meiss R, Elizade P, Charreau E, Pasqualini, CD. Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat 1990; 33.Google Scholar
  17. 17.
    Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell lineT47D. Possible therapeutic implications. Biochem Biophys Res Commun 1987; 45: 706CrossRefGoogle Scholar
  18. 18.
    Braunsburg H, Coldham NG, Wong W. Hormonal therapies for breast cancer: can progestogens stimulate growth? Cancer Letters 1986; 30: 213.CrossRefGoogle Scholar
  19. 19.
    Nesheim BI, Saetre T. Reduction of menopausal hot flashes by methyldopa. Eur J Clin Pharmacol 1981; 20: 413.PubMedCrossRefGoogle Scholar
  20. 20.
    Bergmans MGM, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effects of bellergal retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas 1987; 9: 227.PubMedCrossRefGoogle Scholar
  21. 21.
    Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome. Obstet Gynecol 1969; 33: 795.PubMedGoogle Scholar
  22. 22.
    Goldberg RM, Loprinzi CL, O’Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12: 155.PubMedGoogle Scholar
  23. 23.
    Barton DL, Loprinzi CL, Quella SK, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 1998; 16: 495.Google Scholar
  24. 24.
    Hirata JD, Swiersz LM, Zell B, Small R, Ettinger B. Does dong quai have estrogenic effects on postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997; 68: 981.PubMedCrossRefGoogle Scholar
  25. 25.
    Loprinzi CL, Michalak JC, Quella SK, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347.PubMedCrossRefGoogle Scholar
  26. 26.
    Morrison JC, Martin DC, Blair RA, et al. The use of medroxyprogesterone acetate for relief of climacteric symptoms. Am J Obstet Gynecol 1980; 138: 99.PubMedGoogle Scholar
  27. 27.
    Albrecht BG, Schiff I, Tulchinsky D, Ryan KJ. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am J Obstet Gynecol 1981; 139: 631.PubMedGoogle Scholar
  28. 28.
    Schiff I, Tuschinsky D, Cramer D. Oral medroxyprogesterone acetate in the treatment of postmenopausal symptoms. JAMA 1980; 224: 1443.CrossRefGoogle Scholar
  29. 29.
    Bullock JL, Massey FM, Cambrell RD Jr. Use of medroxyprogesterone acetae to prevent menopausal symptoms. Obstet Gynecol 1975; 46: 165.PubMedGoogle Scholar
  30. 30.
    Mouridsen HT, Elleman K, Mattson W. Therapeutic effect of tamoxifen vs. tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979; 63: 171.PubMedGoogle Scholar
  31. 31.
    Gibson DFC, Johnson DA, Langan-Fahey SM, Lababidi MK, Wolberg WH, Jordan VC. The effects of intermittent progesterone upon tamoxifen inhibition of tumor growth in the 7, 12 dimethylbenzanthracene rat mammary tumor model. Breast Cancer Res Treat 1993; 27: 283.Google Scholar
  32. 32.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1987; 337: 1641.CrossRefGoogle Scholar
  33. 33.
    Fisher B, Constantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J Natl Cancer Inst 1998; 90: 1371.PubMedCrossRefGoogle Scholar
  34. 34.
    Powles TJ, Hickish T, Casey S, O’Brien M. Hormone replacement after breast cancer. Lancet 1993; 342: 60.PubMedCrossRefGoogle Scholar
  35. 35.
    Chang J, Powles TJ, Ashley SE, et al. The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study. Ann Oncol 1996; 7: 671.PubMedCrossRefGoogle Scholar
  36. 36.
    Veronesi U, Maisonneux P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Lancet 1998; 352: 93.PubMedGoogle Scholar
  37. 37.
    Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiologic Study (DOES). Osteoporisis Int 1994; 2: 277.CrossRefGoogle Scholar
  38. 38.
    Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol 1997; 15: 1341.PubMedGoogle Scholar
  39. 39.
    Prince RL. Diet and the prevention of osteoporotic fractures. N Engl J Med 1997; 336: 701.CrossRefGoogle Scholar
  40. 40.
    The writing group for the PEPI trial. Effects of hormone therapy on bone mineral density. JAMA 1996; 276: 1389.Google Scholar
  41. 41.
    Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992; 326: 852.PubMedCrossRefGoogle Scholar
  42. 42.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1998; 337: 1641CrossRefGoogle Scholar
  43. 43.
    McClung M, Clemmesen B, Daifotis A, et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med. 1998; 128: 253.PubMedGoogle Scholar
  44. 44.
    Hosking D, Chilvers CE, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485.PubMedCrossRefGoogle Scholar
  45. 45.
    Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 15: 1016.Google Scholar
  46. 46.
    Kiel DP, Felson DT, Anderson JJ, et al. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 1987; 317: 1169.PubMedCrossRefGoogle Scholar
  47. 47.
    Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437.PubMedCrossRefGoogle Scholar
  48. 48.
    Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner B, Willett WC. Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444.Google Scholar
  49. 49.
    Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to the risk of coronary heart disease among women. JAMA 1998; 279: 359.PubMedCrossRefGoogle Scholar
  50. 50.
    Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14: 1718.PubMedGoogle Scholar
  51. 51.
    Mansour EG, Gray R, Shatila AH, et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 1989; 320: 485PubMedCrossRefGoogle Scholar
  52. 52.
    The Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491.Google Scholar
  53. 53.
    Fisher B, Redmond C, Dimitrov NV, et al. A randomized trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor negative tumors. N Engl J Med 1989; 320: 474.Google Scholar
  54. 54.
    Barrett-Connor E, Bush TL. Estrogen and coronary disease in women. Clinical Cardiology JAMA 1991; 265: 1861.Google Scholar
  55. 55.
    Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med 1991; 325: 756.PubMedCrossRefGoogle Scholar
  56. 56.
    Rosen PP, Groshen S, Kinne DW, et al. Factors influencing prognosis in node negative breast carcinoma: Analysis of 767 T1NOMO/T2NOMO patients with long-term followup. J Clin Oncol 1993; 11: 2090.Google Scholar
  57. 57.
    Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet 1998; 352: 930.Google Scholar
  58. 58.
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997; 89: 1673.PubMedCrossRefGoogle Scholar
  59. 59.
    Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81.Google Scholar
  60. 60.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383.Google Scholar
  61. 61.
    Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels. JAMA 1998; 279: 1615.PubMedCrossRefGoogle Scholar
  62. 62.
    Barrett-Connor E, Bush TL, Estrogen and coronary heart disease in women. Clinical Cardiology JAMA 1991; 265: 1861.Google Scholar
  63. 63.
    Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990; 75(Supp14): 18525 S.Google Scholar
  64. 64.
    Walsh BW, Kuller, LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1988; 279: 1445.CrossRefGoogle Scholar
  65. 65.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451.Google Scholar
  66. 66.
    Clarkson TB, Cline JM, Williams JK, Anthony MS. Gonadal hormone substitutes: effects on the cardiovascular system. Osteoporosis Int 1997; Suppl I: S43.Google Scholar
  67. 67.
    Sam-to T, Blomqvist C, Ehnholm C, Taskinen RM, Elomaa I. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996; 14:429.Google Scholar
  68. 68.
    Anderson JW, Johnstone B, Cook-Newell ME, Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 1995; 333: 276.PubMedCrossRefGoogle Scholar
  69. 69.
    Decensi A, Bonanni B, Guerriieri-Gonzaga A, et al. Biologic activity of tamoxifen at low doses in healthy women. J Natl Cancer Inst 1998; 90: 1461.PubMedCrossRefGoogle Scholar
  70. 70.
    Anthony MS, Clarkson TB, Hughes CI Jr, Morgan TM, Burke GL. Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal rhesus monkeys. J Nutr 1996; 126: 43.PubMedGoogle Scholar
  71. 71.
    Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA 1998; 279: 688.PubMedCrossRefGoogle Scholar
  72. 72.
    Schiff I, Wentworth B, KoosB, Tulchinsky D, Ryan KJ. Effect of estradiol administration on the hypogonadal woman. Fertil Steril 1978; 30: 278.PubMedGoogle Scholar
  73. 73.
    Mattson LA, Cullberg G. Vaginal absorption of two estradiol preparations. Acta Obstet Gynecol Scand 1983; 62: 393.CrossRefGoogle Scholar
  74. 74.
    Heimer GM. Estradiol in the menopause. Acta Obstet Gynecol Scand 1987; Suppl 139: 23 P.Google Scholar
  75. 75.
    Handa VL, Bachus Ke, Johnston WE, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: systemic absorption and effects on the endometrium. Obstet Gynecol 1994; 84: 215.PubMedGoogle Scholar
  76. 76.
    Smith P, Heimer G, Lindskog M, Ulmsten A. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy. Maturitas 16: 145–154, 1993.PubMedCrossRefGoogle Scholar
  77. 77.
    Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 61: 178, 1994.PubMedGoogle Scholar
  78. 78.
    Loprinzi CL, Abu-Ghazaleh Sloan JA, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15: 969, 1997.PubMedGoogle Scholar
  79. 79.
    Cable E, Miracle-McMahill H, Than MJ and Heath C. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 87: 517, 1995.CrossRefGoogle Scholar
  80. 80.
    Grodstein F, Martinez ME, Platz EA, et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 128: 705, 1998.PubMedGoogle Scholar
  81. 81.
    Potter JK, Bostick RM, Grandits GA, et al. Hormone replacement therapy is associated with lower risk of adenomatous polyps of the large bowel: the Minnesota Cancer Prevention research unit case-control study. Cancer Epidemiology, Biomarkers and Prevention 5: 779, 1996.Google Scholar
  82. 82.
    Cline JM, Soderqvist G, von Schoultz E, Skoog L, von Schoultz B. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 174: 93, 1996.PubMedCrossRefGoogle Scholar
  83. 83.
    Laya MB, Gallagher JC, Schreiman JS, et al. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 196: 433, 1995.PubMedGoogle Scholar
  84. 84.
    McNicholas MMJ, Geneghan JP, Milner MH, et al. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR 163: 311, 1994.PubMedGoogle Scholar
  85. 85.
    Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogenprogestin replacement regimens on mammographic breast parenchymal density. J. Clin Oncol 15: 3201, 1997.PubMedGoogle Scholar
  86. 86.
    Kelsey JL, Berkowitz GS. Breast cancer epidemiology. Cancer Res 48: 5615, 1988.PubMedGoogle Scholar
  87. 87.
    Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–1982. In: Boice JD Jr, Storm HH, Curtis RE, eds. Multiple primary cancers in Connecticut and Denmark. National Cancer Institute monograph 68. Washington, D.C.: Government Printing Office, 99–112, 1985 (NIH publication no. 85–2714).Google Scholar
  88. 88.
    Henrich JB. The postmenopausal estrogen/breast cancer controversy. JAMA 268: 1900, 1992.PubMedCrossRefGoogle Scholar
  89. 89.
    DuPont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151: 67, 1991.PubMedCrossRefGoogle Scholar
  90. 90.
    Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265: 1985, 1991.PubMedCrossRefGoogle Scholar
  91. 91.
    Armstrong BK. Oestrogen therapy after the menopause - boon or bane? Med J Aust 248: 113, 1988.Google Scholar
  92. 92.
    Grady D, Ernster V. Invited commentary: Does postmenopausal hormone therapy cause breast cancer? Am J Epidemiol 134: 1396, 1991.Google Scholar
  93. 93.
    Sillero-Arenas M, Delgado-Rodriguez M, Rodrigues-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: a meta-analysis. Obstet Gynecol 79: 286, 1992.PubMedGoogle Scholar
  94. 94.
    Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168: 1473, 1993.PubMedGoogle Scholar
  95. 95.
    Ginsburg ES, Mello NK, Mendelson JK, et al. Effects of alcohol ingestion on estrogens in postmenopausal women. JAMA 276: 1747, 1996.PubMedCrossRefGoogle Scholar
  96. 96.
    Nayfield SG, Karp JE, Ford LG, et al. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450, 1991.PubMedCrossRefGoogle Scholar
  97. 97.
    Persson I, Yuen J, Gergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67: 327, 1996.PubMedCrossRefGoogle Scholar
  98. 98.
    Gambrell DR. Proposal to decrease the risk and improve the prognosis in breast cancer. Am J Obstet Gynecol 150: 119, 1984.PubMedGoogle Scholar
  99. 99.
    Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynecol 94: 620, 1987.CrossRefGoogle Scholar
  100. 100.
    Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151: 75, 1991.PubMedCrossRefGoogle Scholar
  101. 101.
    Criqui MH, Suarez L, Barrett-Connor E, et al. Postmenopausal estrogen use and mortality. Am J Epidemiol 128: 606, 1988.PubMedGoogle Scholar
  102. 102.
    Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 49: 526, 1991.PubMedCrossRefGoogle Scholar
  103. 103.
    Wilis DB, Calle EE, Miracle-McMahill HL, Heath Jr CW. Cancer Causes and Control. 7: 449–457, 1996.CrossRefGoogle Scholar
  104. 104.
    Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 332: 1589, 1995.PubMedCrossRefGoogle Scholar
  105. 105.
    Dao TL, Sinha DI, Nemoto T, Patel J. Effect of estrogen and progesterone on cellular replication of human breast tumors. Cancer Res 42: 359, 1982.PubMedGoogle Scholar
  106. 106.
    Fabian CJ, Kimler BF, McKittrick R, et al. Recruitment with high physiological doses of estradiol preceding chemotherapy: flow cytometric and therapeutic results in women with locally advanced breast cancer — a Southwest Oncology Group Study. Cancer Res 54: 5357, 1994.PubMedGoogle Scholar
  107. 107.
    Dhodapkar MV, Ingle NJ, Ahmann DL. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75: 43, 1995.PubMedCrossRefGoogle Scholar
  108. 108.
    Powles TJ, Hickish T. Breast cancer response to hormone replacement therapy withdrawal. Lancet 345: 1442, 1995.PubMedCrossRefGoogle Scholar
  109. 109.
    Harvey SC, DiPiro PJ, Meyer JE. Marked regression of a nonpalpable breast cancer after cessation of hormone replacement therapy. AJR 167: 394, 1996.PubMedGoogle Scholar
  110. 110.
    Cobleigh MA. Hormone replacement therapy in breast cancer survivors. In: Diseases of the Breast Updates. Harris JR, Lippman ME, eds. 1:1, 1997.Google Scholar
  111. 111.
    Eden JA, Bush T, Nand S, Wren BG. The Royal Hospital for Women Breast Cancer Study: a case-controlled study of combined continuous hormone replacement therapy amongst women with a personal history of breast cancer. Menopause 2: 67, 1995.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2000

Authors and Affiliations

  • Melody A. Cobleigh
    • 1
  1. 1.Rush-Presbyterian-St.Luke’s Medical CenterUSA

Personalised recommendations